

Wellnex Life Limited (ASX:WNX)

Trading Update YTD FY25

Announcement highlights

- Total sales for Jul-Dec FY25 increased to \$11.94 million, up 112% compared to the same period for FY24 (\$5.63 million).
- Strong brand sales in the period, increasing 182% in FY25 (\$8.47 million) compared to the same period in FY24 (\$3.0 million)
- Momentum increasing, with 1018% increase of sales recorded for December 2024 (\$3.02 million), compared to December 2023 (\$0.27 million).

Wellnex Life Limited (ASX:WNX) (“Wellnex” or “the Company”) is pleased to provide a company update for the July to December 2024 period, which included another strong month in December with sales of \$3.02 million.

Sales in December increased to \$3.02 million, up 1018% compared to December 2023 (\$0.27 million), with growth continuing to come across the whole business.

	December 2023	December 2024	% Change
Brands	\$0.27 million	\$2.0 million	640%
IP Licensing	\$0	\$1.02 million	N/A
Total	\$0.27 million	\$3.02 million	1018%

Wellnex is now seeing continued growth with sales for the first 6 months of FY25 (\$11.94 million) up 112% compared to the same period for FY24 (\$5.63 million).

	July – Dec 2023	July – Dec 2024	% Change
Brands	\$3.0 million	\$8.47 million	182%
IP Licensing	\$2.12 million	\$3.47 million	64%
Brokerage	\$0.51 million	\$0	N/A
Total	\$5.63 million	\$11.94 million	112%

The board looks forward to reporting further progress as we move into the remainder of FY25, benefiting from the continued expansion of Wellnex’s brands in both distribution and awareness, growth in its IP licensing business.

Wellnex Life Limited

For personal use only

This ASX announcement has been authorised by the Board of Wellnex Life Limited (ASX:WNX)

For further information, please contact:

Wellnex Life Limited (ASX:WNX)

George Karafotias

Chief Executive Officer

P: +61 3 8399 9419

E: george.k@wellnexlife.com.au

About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently acquired leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.wellnexlife.com.au/

For personal use only